He X, Fu Y, Xu Y, Ma L, Chai P, Shi H
Invest Ophthalmol Vis Sci. 2025; 66(1):6.
PMID: 39745676
PMC: 11702840.
DOI: 10.1167/iovs.66.1.6.
Zakas P, Cunningham S, Doherty A, van Dijk E, Ibraheim R, Yu S
Mol Ther. 2024; 32(10):3356-3371.
PMID: 38981468
PMC: 11489535.
DOI: 10.1016/j.ymthe.2024.06.021.
Long B, Robinson T, Day J, Yu H, Lau K, Imtiaz U
Mol Ther. 2024; 32(7):2052-2063.
PMID: 38796703
PMC: 11286804.
DOI: 10.1016/j.ymthe.2024.05.033.
Liang S, Navia A, Ramseier M, Zhou X, Martinez M, Lee C
Hum Gene Ther. 2024; 35(19-20):814-824.
PMID: 38767512
PMC: 11511778.
DOI: 10.1089/hum.2024.035.
Giannelli S, Luoni M, Iannielli A, Middeldorp J, Philippens I, Bido S
iScience. 2024; 27(5):109777.
PMID: 38711458
PMC: 11070337.
DOI: 10.1016/j.isci.2024.109777.
AAV for Gene Therapy in Ocular Diseases: Progress and Prospects.
He X, Fu Y, Ma L, Yao Y, Ge S, Yang Z
Research (Wash D C). 2024; 6:0291.
PMID: 38188726
PMC: 10768554.
DOI: 10.34133/research.0291.
Analysis of vector genome integrations in multicentric lymphoma after AAV gene therapy in a severe hemophilia A dog.
Van Gorder L, Doshi B, Willis E, Nichols T, Cook E, Everett J
Mol Ther Methods Clin Dev. 2023; 31:101159.
PMID: 38094200
PMC: 10716008.
DOI: 10.1016/j.omtm.2023.101159.
Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy.
Kashiwakura Y, Endo K, Ugajin A, Kikuchi T, Hishikawa S, Nakamura H
Mol Ther Methods Clin Dev. 2023; 30:502-514.
PMID: 37693948
PMC: 10491835.
DOI: 10.1016/j.omtm.2023.08.016.
Vector Affinity and Receptor Distribution Define Tissue-Specific Targeting in an Engineered AAV Capsid.
Martino R, Wang Q, Xu H, Hu G, Bell P, Arroyo E
J Virol. 2023; 97(6):e0017423.
PMID: 37199615
PMC: 10308920.
DOI: 10.1128/jvi.00174-23.
Delivery challenges for CRISPR-Cas9 genome editing for Duchenne muscular dystrophy.
Padmaswari M, Agrawal S, Jia M, Ivy A, Maxenberger D, Burcham L
Biophys Rev (Melville). 2023; 4(1):011307.
PMID: 36864908
PMC: 9969352.
DOI: 10.1063/5.0131452.
Gene therapy for liver diseases - progress and challenges.
Zabaleta N, Unzu C, Weber N, Gonzalez-Aseguinolaza G
Nat Rev Gastroenterol Hepatol. 2023; 20(5):288-305.
PMID: 36646909
DOI: 10.1038/s41575-022-00729-0.
Current advances in gene therapy of mitochondrial diseases.
Soldatov V, Kubekina M, Skorkina M, Belykh A, Egorova T, Korokin M
J Transl Med. 2022; 20(1):562.
PMID: 36471396
PMC: 9724384.
DOI: 10.1186/s12967-022-03685-0.
Systemic administration of novel engineered AAV capsids facilitates enhanced transgene expression in the macaque CNS.
Stanton A, Lagerborg K, Tellez L, Krunnfusz A, King E, Ye S
Med. 2022; 4(1):31-50.e8.
PMID: 36417917
PMC: 9840684.
DOI: 10.1016/j.medj.2022.11.002.
Allometric-like scaling of AAV gene therapy for systemic protein delivery.
Burr A, Erickson P, Bento R, Shama K, Roth C, Parekkadan B
Mol Ther Methods Clin Dev. 2022; 27:368-379.
PMID: 36381306
PMC: 9641010.
DOI: 10.1016/j.omtm.2022.10.011.
Treating Transthyretin Amyloidosis via Adeno-Associated Virus Vector Delivery of Meganucleases.
Greig J, Breton C, Ashley S, Martins K, Gorsuch C, Chorazeczewski J
Hum Gene Ther. 2022; 33(21-22):1174-1186.
PMID: 36375122
PMC: 9700363.
DOI: 10.1089/hum.2022.061.
Rational engineering of adeno-associated virus capsid enhances human hepatocyte tropism and reduces immunogenicity.
Han J, Zhu L, Zhang J, Guo L, Sun X, Huang C
Cell Prolif. 2022; 55(12):e13339.
PMID: 36135100
PMC: 9715358.
DOI: 10.1111/cpr.13339.
Application of --cultured primary hepatocytes to evaluate species translatability and AAV transduction mechanisms of action.
Liu S, Razon L, Ritchie O, Sihn C, Handyside B, Berguig G
Mol Ther Methods Clin Dev. 2022; 26:61-71.
PMID: 35782594
PMC: 9204658.
DOI: 10.1016/j.omtm.2022.05.008.
Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A.
Klamroth R, Hayes G, Andreeva T, Gregg K, Suzuki T, Mitha I
Hum Gene Ther. 2022; 33(7-8):432-441.
PMID: 35156839
PMC: 9063149.
DOI: 10.1089/hum.2021.287.
dCas9-VPR-mediated transcriptional activation of functionally equivalent genes for gene therapy.
Riedmayr L, Hinrichsmeyer K, Karguth N, Bohm S, Splith V, Michalakis S
Nat Protoc. 2022; 17(3):781-818.
PMID: 35132255
DOI: 10.1038/s41596-021-00666-3.
Determining the Minimally Effective Dose of a Clinical Candidate Adeno-Associated Virus Vector in a Mouse Model of Hemophilia A.
Greig J, Smith M, Nordin J, Goode T, Chroscinski E, Buza E
Hum Gene Ther. 2021; 33(7-8):421-431.
PMID: 34652966
PMC: 9063151.
DOI: 10.1089/hum.2021.108.